Sofosbuvir works by inhibiting the RNA polymerase that the hepatitis C virus uses to replicate its RNA. In combination with other therapies, sofosbuvir can effectively cure hepatitis in 90% of patients.

According to Bloomberg, Gilead is close to completing the licensing deal which will permit generics makers to make generic sofosbuvir and one more candidate combining Sovaldi with another of Gilead’s hepatitis treatments. The deal could come into effect from the middle of September 2014. Gilead is currently in talks with five or six generics makers, including Indian generics makers Cipla and Mylan.

The World Health Organization estimates that about 3% of the world’s population has been infected with the hepatitis C virus and that more than 170 million chronic carriers are at risk of developing liver cirrhosis, liver cancer or both. Around 350,000 people are thought to die from the virus each year [1].

Gilead also plans to sell the brand-name version of Sovaldi in India for US$900 for 12 weeks of therapy. In the US, the drug sells for US$1,000 a pill, or US$84,000 for 12 weeks. Patients normally stay on the drug for 12 or 24 weeks.

The news follows a July 2014 announcement by Gilead that the company had made a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide for the treatment of HIV and hepatitis B, depending on its US Food and Drug Administration approval. Under this agreement, the MPP can sub-license tenofovir alafenamide to generics companies in China and India, who may manufacture and distribute it in 112 developing countries.

Related Article
Gilead makes HIV generics deal

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Improving access to HCV treatment in developing countries [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Sep 12]. Available from: www.gabionline.net/Biosimilars/Research/Improving-access-to-HCV-treatment-in-developing-countries

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.